352 related articles for article (PubMed ID: 15846363)
1. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
[TBL] [Abstract][Full Text] [Related]
2. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
3. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
[TBL] [Abstract][Full Text] [Related]
4. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
[TBL] [Abstract][Full Text] [Related]
5. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
6. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Crawford LJ; Walker B; Ovaa H; Chauhan D; Anderson KC; Morris TC; Irvine AE
Cancer Res; 2006 Jun; 66(12):6379-86. PubMed ID: 16778216
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
8. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Altun M; Galardy PJ; Shringarpure R; Hideshima T; LeBlanc R; Anderson KC; Ploegh HL; Kessler BM
Cancer Res; 2005 Sep; 65(17):7896-901. PubMed ID: 16140960
[TBL] [Abstract][Full Text] [Related]
9. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
15. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
Landowski TH; Megli CJ; Nullmeyer KD; Lynch RM; Dorr RT
Cancer Res; 2005 May; 65(9):3828-36. PubMed ID: 15867381
[TBL] [Abstract][Full Text] [Related]
18. Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J; Kauffman M
Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.
Goranov SE; Goranova-Marinova VS
Folia Med (Plovdiv); 2005; 47(3-4):11-9. PubMed ID: 16761388
[TBL] [Abstract][Full Text] [Related]
20. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Birle DC; Hedley DW
Cancer Res; 2007 Feb; 67(4):1735-43. PubMed ID: 17308115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
